Dublin, Dec. 04, 2019 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer - Markets, Strategies & Trends, Forecasts By Cancer Type & By Country - With Executive and Consultant Guides - 2020 To 2024" report has been added to ResearchAndMarkets.com's offering.
This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2019 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.
A market that just keeps on growing. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations.
Trends such as:
Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.
In addition to customization work, breakouts for particular segments, assistance and support is included free of charge with every report.
Key Topics Covered
1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 Methodology
1.5 U.S. Medical Market and laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Laboratory Testing
2. Market Overview
2.1 Market Participants
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab's
2.3.4 Physician's and POCT
3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 Testing as a Controllable Cost
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role.
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing.
3.4.2 Shifting Role of Diagnostics
3.4.3 Multiplexing and Foundation One
3.4.4 Pharmacogenomics Technology
3.4.5 Whole Genome Sequencing
3.4.6 Gene Editing and Gene Therapy
4. Molecular Diagnostics Recent Developments
5. Profiles of Key MDx Companies
6. The Global Market for MDx Cancer
6.1 MDx Cancer - Global Market Overview by Country
6.1.1 Table - Global Market by Country
6.1.2 Chart - Global Market by Country
7. Global MDx Cancer Markets - By Type of Cancer
7.1 Global Market by Cancer Type - Overview
7.2 MDx Breast Cancer
7.3 MDx Colorectal Cancer
7.4 MDx Cervical Cancer
7.5 MDx Lung Cancer
7.6 MDx Precancer
7.7 MDx Prostate Cancer
7.8 MDx Melanoma
7.9 MDx Blood Cancer
7.10 MDx Other Cancer
8. Cancer Treatment and Trials
8.1 FDA Cancer Drug Approvals by Year
8.2 Clinical Trials Started 2010 to 2016
8.3 Prevalence of Cancer Treatments - 2015
Appendices
I. United States Medicare System: January 2019 Clinical Laboratory Fees Schedule
II. FDA Approved Human Genetic Tests
III. FDA Approved Microbial Tests
IV. FDA Approved Pharmacogenomics Tests
For more information about this report visit https://www.researchandmarkets.com/r/xwwbho
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.